Cosmax Group Expands Microbiome Research with Mass General Brigham
Korean cosmetics firm Cosmax Group extended its VIVA Project with Harvard-affiliated Mass General Brigham on October 13, pushing into functional food ingredients and drug development.
Partnership Extends Beyond Cosmetics
Cosmax Group, a major Korean cosmetics manufacturer, announced on October 13 an expanded microbiome research partnership with Mass General Brigham. This network of Harvard Medical School-affiliated teaching hospitals signed an agreement with Cosmax at Massachusetts General Hospital in Boston.
The collaboration marks the launch of the second phase of their joint VIVA Project, strategically pushing Cosmax Group beyond its traditional beauty product focus into health supplements and pharmaceutical development. Cosmax Group Chairman Lee Kyung-soo and Mass General Brigham Chief Development Officer Mike McNally were present at the signing ceremony.
New Research Focus on Functional Foods and Drugs
The new phase of the VIVA Project is scheduled to run from 2026 to 2029. It will significantly broaden the scope of research to include functional food ingredients and potential drug candidates. This builds upon the foundational work completed in skin microbiome technology during the first phase.
Researchers plan to use Mass General Brigham's extensive clinical infrastructure to evaluate the efficacy and safety of new candidate substances, with a particular emphasis on applications for antiaging and promoting healthy aging.
Additionally, the project will explore probiotics and functional food ingredients that operate through mechanisms similar to glucagon-like peptide-1 (GLP-1), targeting weight and metabolic management. Artificial intelligence will be deployed to identify research targets and optimize candidate substances, aiming to accelerate the development process.
Phase One Achievements and Patent Filing
During the first phase of the partnership, which took place from 2024 to 2026, researchers successfully combined Cosmax's proprietary skin microbiome data with Mass General Brigham's clinical data. This collaborative effort led to the identification of a microorganism-derived substance.
Initial findings indicated that this substance alleviated symptoms in an atopic dermatitis model and improved skin barrier function. These research outcomes were subsequently published in the international journal Allergy.
Following these discoveries, Cosmax Group filed a Korean patent application for the associated technology, securing intellectual property for its innovations in this field.
Implications for Asian Beauty and Health
This expansion underscores Cosmax Group's strategic pivot towards establishing technological leadership in the biotechnology and medical sectors, moving beyond its core cosmetics business. For Asian beauty companies, this development signals a growing trend of convergence between beauty, health, and pharmaceuticals, driven by scientific research and clinical validation.
Companies seeking growth may consider integrating advanced health solutions into their portfolios, similar to Cosmax's move. Separately, Cosmax has also established a development and production system for Class II adhesive transparent wound dressings, backed by Good Manufacturing Practice (GMP) compliance recognition.
This further illustrates the company's diversification into regulated medical product categories, indicating a potential future for beauty manufacturers in adjacent, high-value health markets.
Three newsletters, one newsroom.
The Beauty Brief delivers Asia's beauty week every Monday. Regulatory Radar tracks the rule changes that move markets. Trend Pulse decodes what consumers want next. All free to start.
